COLOPLAST Logo
DK0060448595
A1KAGC
CBHD.DE

COLOPLAST

Se i Terminal

Kurser indlĂŠses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet


  • Coloplast A-S announces quarterly results for 03.11.2026

    Coloplast A-S will release results on 03.11.2026 for the quarter ended 30.09.2026. Eleven analysts on average estimate EPS for the quarter at 5.91 DKK versus 3.88 DKK a year earlier, and 15 analysts forecast revenue of 7.40 bn DKK versus 6.96 bn DKK in the year-ago quarter. For the most recently completed fiscal year, 22 analysts predict EPS of 25.45 DKK (prev. year 16.13 DKK) and 23 analysts expect annual revenue of 28.88 bn DKK (prev. year 27.87 bn DKK). » Mere pÄ finanzen.net


  • Coloplast A-S expects slight revenue growth and higher EPS for Q3, results on Nov. 3

    Coloplast A-S will release results for the quarter ended Sept. 30 on Nov. 3. Ten analysts see an average EPS of USD 0.090 versus USD 0.060 a year earlier. Quarterly revenues are forecast on average at USD 1.12 billion (+2.6% year-on-year). For the past fiscal year analysts on average expect EPS of USD 0.385 and revenue of USD 4.38 billion. » Mere pÄ finanzen.net


  • Coloplast share falls after downgrade by JPMorgan

    Coloplast’s share dropped 3.3% and fell intraday to as low as 427.8 DKK after JPMorgan cut its rating from "Neutral" to "Underweight" and lowered the December 2027 price target from 484 DKK to 377 DKK (about −22%). The bank cited a high P/E ratio of 35.35 and a valuation premium of roughly 20% versus the medtech sector, while earnings growth lags the industry. JPMorgan also noted governance uncertainty and expects the new CEO is likely to revise mid‑term financial targets down when results are presented on 3 November; weak Q3 margins and increased short interest add further pressure. » Mere pĂ„ de.investing.com


  • Coloplast A-S (B) announces quarterly results for period to 30 June 2026

    Coloplast A-S (B) will present the numbers for the quarter to 30 June 2026 on 18 August 2026. Ten analysts expect on average an EPS of 6.08 DKK versus 3.57 DKK in the prior year. Fourteen analysts forecast revenue of on average 7.26 billion DKK, an increase of 4.34% versus the year-earlier quarter. For the current fiscal year, consensus estimates are 24.88 DKK earnings per share and 28.79 billion DKK revenue. » Mere pÄ finanzen.net


  • Coloplast A-S (spons ADRs) announces quarterly results for June 30, 2026

    Coloplast A-S (spons ADRs) will present results for the quarter ended June 30, 2026 on August 18, 2026. Nine analysts expect EPS of on average $0.093 (prior year $0.050); 13 analysts forecast revenue of about $1.11 billion (up 5.4% from $1.06 billion). For the current fiscal year, consensus estimates are $0.382 EPS and $4.43 billion in revenue (prior year: $0.240 / $4.12 billion). » Mere pÄ finanzen.net

I 2026 har COLOPLAST allerede udloddet 0,67 € i udbytte. Den seneste udlodning fandt sted i maj.

Virksomhedstal

I det seneste kvartal havde COLOPLAST en omsĂŠtning pĂ„ 7,44 mia. € og et nettoresultat pĂ„ 1,18 mia. €
(EUR) september 2026
YoY
OmsÊtning 7,44 mia. 105,80 %
Bruttofortjeneste 4,87 mia. 24,73 %
Nettoresultat 1,18 mia. 35,56 %
EBITDA 2,1 mia. 106,10 %

Fundamentale data

NĂžgletal VĂŠrdi
MarkedsvĂŠrdi
14,88 mia. €
Antal aktier
225,37 mio.
HĂžjeste/laveste i 52 uger
86,62 € - 49,48 €
Udbytteafkast
4,64 %
Udbytte TTM
3,08 €
Beta
0,55
P/E (PE Ratio)
36,08
PEG (PEG Ratio)
-2,34
K/I (PB Ratio)
7,76
P/S (PS Ratio)
3,83

Virksomhedsprofil

Coloplast A/S udvikler, fremstiller og markedsfÞrer medicinske produkter. Virksomheden er engageret i udvikling, markedsfÞring og salg af produkter og services til intim sundhedspleje, rettet mod personer med sygdomme af privat og personlig karakter. Dens aktiviteter er opdelt i fire forretningsomrÄder: Ostomy Care, som tilbyder produkter til personer, hvis tarmudgang er blevet flyttet gennem bugvÊggen; Continence Care, som tilbyder produkter til personer med sygdomme i og skader pÄ urinsystemet; Urology Care, som tilbyder produkter til personer med sygdomme i og skader pÄ nyrerne, urinsystemet eller det mandlige reproduktionssystem; og Wound & Skin Care til behandling af kroniske sÄr og hudplejeprodukter til forebyggelse og behandling. Virksomheden leverer produkter til hospitaler, institutioner samt grossister og apoteker.

Navn
COLOPLAST
CEO
Gavin Wood
Hjemsted HumlebĂŠk, ze
Danmark
Websted
Sektor
Sundhed
Branche
Sundhedsudstyr og -produkter
BĂžrsnotering
24.01.2007
Medarbejdere 17.524

Tickersymboler

BĂžrs Symbol
XETRA
CBHD.DE
Pnk
CLPBF
Nasdaq Copenhagen
COLO-B.CO
Copenhagen
COLO B.CO
Frankfurt
CBHD.F
DĂŒsseldorf
CBHD.DU
London
0QBO.L
SIX
COLOB.SW
MĂŒnchen
CBHD.MU
Wien
COLO.VI
đŸȘ

Parqet  bruger cookies. LÊs mere